Dexmedetomidine (Dex), a highly selective α2-adrenergic receptor (α2AR) agonist, can reduce pulmonary edema through inhibiting the production of inflammatory cytokines, including TNF-α, IL-1β, and IL-6 in an ALI model [13–16]. Here, IL6 is linked to acute respiratory distress syndrome.